Citadel Advisors’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
Other funds holding ALDX
KCM
KCM
6CM
Citadel Advisors's ALDX Position: Q3 2026 in Review
Citadel Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 35% in Q3 2026, selling an estimated $213K and leaving 245,677 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #11381.
Citadel Advisors first reported a position in ALDX in Q1 2018 and has held it in 32 quarters since. The position peaked at $11M in Q1 2022. 97 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.
- Citadel Advisors held 245,677 shares of Aldeyra Therapeutics worth $302K as of Q3 2026.
- Citadel Advisors sold 133,467 Aldeyra Therapeutics shares in Q3 2026, an estimated $213K.
- Aldeyra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #11381 holding.
- Citadel Advisors first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 32 quarters since.
- Citadel Advisors's Aldeyra Therapeutics position peaked at $11M in Q1 2022.
- 97 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.